|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.42 CAD | -1.03% |
|
-0.55% | +13.28% |
| 05-22 | BioSyent Inc., Q1 2026 Earnings Call, May 14, 2026 | |
| 05-19 | BioSyent Secures Health Canada Nod For Hypothyroidism Oral Solution | MT |
| Market Cap | 167M 117M 103M 94.85M 87.87M 11.15B 169M 1.14B 441M 5.5B 441M 431M 19.02B | P/E 2026 * |
16.4x | P/E 2027 * | 13.5x |
|---|---|---|---|---|---|
| Enterprise Value | 167M 117M 103M 94.85M 87.87M 11.15B 169M 1.14B 441M 5.5B 441M 431M 19.02B | EV / Sales 2026 * |
2.42x | EV / Sales 2027 * | 2.02x |
| Free-Float |
64.48% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: BioSyent Inc.
| 1 day | -1.03% | ||
| 1 week | -0.55% | ||
| Current month | -0.55% | ||
| 1 month | +4.12% | ||
| 3 months | +0.07% | ||
| 6 months | +14.35% | ||
| Current year | +13.28% |
| 1 week | 14.42 |  | 14.64 |
| 1 month | 13.51 | | 14.7 |
| Current year | 12.25 | | 15.8 |
| 1 year | 10.65 | | 15.8 |
| 3 years | 7.41 | | 15.8 |
| 5 years | 6.24 | | 15.8 |
| 10 years | 3.13 | | 15.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
René Goehrum
CEO | Chief Executive Officer | 66 | 1999-04-30 |
Robert March
DFI | Director of Finance/CFO | - | 2018-09-09 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 2015-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
René Goehrum
CHM | Chairman | 66 | 1999-05-31 |
Peter Lockhard
BRD | Director/Board Member | 62 | 2002-05-31 |
Stephen Wilton
BRD | Director/Board Member | 65 | 2014-01-15 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 06-22 | Option | Chief Technology Officer | -400 | 0.0035% | ||
| 06-21 | Option | Chief Technology Officer | -2,500 | 0.0217% | ||
| 06-21 | Buy | Director | -74 | 0.0006% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.03% | -0.55% | +21.18% | +92.52% | 117M | |
| +2.96% | +3.01% | +59.87% | +173.31% | 1,070B | |
| +3.05% | +5.23% | +72.11% | +67.81% | 624B | |
| -0.04% | +1.20% | +35.72% | +87.93% | 450B | |
| -2.58% | -2.07% | +27.62% | +22.57% | 328B | |
| +1.36% | +0.17% | +29.90% | +49.33% | 284B | |
| +1.98% | +4.08% | -25.78% | -39.02% | 217B | |
| +0.45% | +1.65% | +25.65% | +68.35% | 198B | |
| +5.21% | +7.93% | +21.99% | +83.23% | 161B | |
| +1.48% | -0.04% | -4.64% | -32.25% | 135B | |
| Average | +0.68% | +2.30% | +26.36% | +57.38% | 346.76B | |
| Weighted average by Cap. | +0.29% | +2.51% | +41.85% | +87.34% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 69M 48.54M 42.6M 39.27M 36.38M 4.61B 70.16M 471M 183M 2.28B 182M 178M 7.88B | 82.3M 57.9M 50.81M 46.84M 43.39M 5.5B 83.69M 562M 218M 2.71B 218M 213M 9.39B |
| Net income | - | - |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-07 | $14.42 | -1.03% | 3,170 |
| 26-07-06 | $14.57 | +0.48% | 2,454 |
| 26-07-03 | $14.50 | +0.42% | 2,723 |
| 26-07-02 | $14.44 | -0.41% | 2,573 |
| 26-06-30 | $14.50 | -1.29% | 7,463 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
14.57CAD
Average target price
18.00CAD
Spread / Average Target
+23.54%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RX Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
